Form 4 for URGN UroGen Pharma Ltd.
Accepted 2022-01-28 00:00:00 ET · period of report 2022-01-26 · accession 0001209191-22-005416 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-01-28 | 2022-01-26 | URGN | Schoenberg Mark | Chief Medical Off | M - OptEx | — | +209 | 22.2K | +1.0% | — |
| D | 2022-01-28 | 2022-01-26 | URGN | Schoenberg Mark | Chief Medical Off | S - Sale+OE | $8.09 | -111 | 22.1K | -0.5% | -$897.99 |
| D | 2022-01-28 | 2022-01-26 | URGN | Schoenberg Mark | Chief Medical Off | M - OptEx | $0.00 | -209 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2022-01-26 | M | A | 209 | — | 22,206 | D | — | — | (F1) Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer |
| 2 | Common | Ordinary Shares | 2022-01-26 | S | D | 111 | $8.09 | 22,095 | D | — | — | (F2) Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units |
| 3 | Derivative | Restricted Stock Units | 2022-01-26 | M | D | 209 | $0.00 | 0 | D | — · — to — | 209 Ordinary Shares | (F1) Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer (F3) The reporting person was granted restricted stock units ("RSUs") on January 26, 2019 representing 2,500 ordinary shares. 33.33% of the RSUs vested on January 26, 2020 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter. |